Anthony Shields, M.D., Ph.D. | Karmanos ...

Dr. Anthony F. Shields

Claim this profile

Barbara Ann Karmanos Cancer Institute

Studies Cancer
Studies Solid Tumors
22 reported clinical trials
65 drugs studied

Area of expertise

1Cancer
Anthony F. Shields has run 8 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
dMMR positive
2Solid Tumors
Anthony F. Shields has run 8 trials for Solid Tumors. Some of their research focus areas include:
Stage IV
Stage III
dMMR positive

Affiliated Hospitals

Image of trial facility.
Barbara Ann Karmanos Cancer Institute
Image of trial facility.
Wayne State University/Karmanos Cancer Institute

Clinical Trials Anthony F. Shields is currently running

Image of trial facility.

TAB004 + Toripalimab

for Solid Cancers

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
Image of trial facility.

Gemcitabine + Nab-paclitaxel + TheraBionic P1

for Pancreatic Cancer

The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pancreas.
Recruiting1 award Phase 24 criteria

More about Anthony F. Shields

Clinical Trial Related5 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 9 Active Clinical Trials
Treatments Anthony F. Shields has experience with
  • Gemcitabine
  • Ipilimumab
  • Capecitabine
  • Fluorouracil
  • Nivolumab
  • Leucovorin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Anthony F. Shields specialize in?
Is Anthony F. Shields currently recruiting for clinical trials?
Are there any treatments that Anthony F. Shields has studied deeply?
What is the best way to schedule an appointment with Anthony F. Shields?
What is the office address of Anthony F. Shields?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security